Search Results - "van Dalen, E C"

Anthracycline-Induced Clinical Heart Failure in a Cohort of 607 Children: Long-Term Follow-Up Study by KREMER, L. C. M, VAN DALEN, E. C, OFFRINGA, M, OTTENKAMP, J, VOUTE, P. A

“…To determine the early and late cumulative incidence of anthracycline-induced clinical heart failure (A-CHF) after anthracycline therapy in childhood and to…”
Get full text

Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review by Kremer, L. C. M., van der Pal, H. J. H., Offringa, M., van Dalen, E. C., Voûte, P. A.

“…Background The aim of this systematic review was to summarise and appraise the published evidence with regard to the frequency and risk factors of subclinical…”
Get full text

Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review by Kremer, L. C. M., van Dalen, E. C., Offringa, M., Voûte, P. A.

“…Background Anthracyclines are essential for the treatment of the children with cancer. We performed a systematic review to evaluate the existing evidence of…”
Get full text

Risk Prediction Models for Myocardial Dysfunction and Heart Failure in Patients with Current or Prior Cancer by van Dalen, E. C., Leerink, J. M., Kremer, L. C. M., Feijen, E. A. M.

“…Purpose of Review Cancer patients are at risk for treatment-related myocardial dysfunction and heart failure during or after treatment. Risk prediction models…”
Get full text

The volume effect in paediatric oncology: a systematic review by Knops, R.R.G., van Dalen, E.C., Mulder, R.L., Leclercq, E., Knijnenburg, S.L., Kaspers, G.J.L., Pieters, R., Caron, H.N., Kremer, L.C.M.

“…For several adult cancer types, there is evidence that treatment in high volume hospitals, high case volume providers, or in specialised hospitals leads to a…”
Get full text

Cumulative incidence and risk factors of mitoxantrone-induced cardiotoxicity in children: a systematic review by van Dalen, E.C, van der Pal, H.J.H, Bakker, P.J.M, Caron, H.N, Kremer, L.C.M

“…Mitoxantrone is believed to maintain anthracycline antitumour activity but be associated with a reduced cardiotoxicity. The aim of this study was to evaluate…”
Get full text

The Dutch Childhood Oncology Group guideline for follow-up of asymptomatic cardiac dysfunction in childhood cancer survivors by Sieswerda, E., Postma, A., van Dalen, E.C., van der Pal, H.J.H., Tissing, W.J.E., Rammeloo, L.A.J., Kok, W.E.M., van Leeuwen, F.E., Caron, H.N., Kremer, L.C.M.

“…The Late Effects of Childhood Cancer task force of the Dutch Childhood Oncology Group (DCOG LATER) developed a guideline for follow-up of asymptomatic cardiac…”
Get full text

Protein Adsorption Enhances Energy Dissipation in Networks of Lysozyme Amyloid Fibrils by van Dalen, Maurice C. E, Vaneyck, Jonathan, Semerdzhiev, Slav A, Karperien, Marcel, Post, Janine N, Claessens, Mireille M. A. E

“…Hydrogels of amyloid fibrils are a versatile biomaterial for tissue engineering and other biomedical applications. Their suitability for these applications has…”
Get full text

The use of liposomal anthracycline analogues for childhood malignancies: A systematic review by Sieswerda, E, Kremer, L.C.M, Caron, H.N, van Dalen, E.C

“…Abstract In an effort to prevent or reduce anthracycline-induced cardiotoxicity, liposomal anthracyclines have been developed. The objective of this systematic…”
Get full text

Cardioprotective interventions for cancer patients receiving anthracyclines by van Dalen, E C, Caron, H N, Dickinson, H O, Kremer, L C M

“…Anthracyclines are among the most effective chemotherapeutic agents in the treatment of numerous malignancies. Unfortunately, their use is limited by a…”
Get more information

Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children by Visscher, H., Ross, C.J.D., Rassekh, S.R., Sandor, G.S.S., Caron, H.N., van Dalen, E.C., Kremer, L.C., van der Pal, H.J., Rogers, P.C., Rieder, M.J., Carleton, B.C., Hayden, M.R.

“…Background . The use of anthracyclines as effective antineoplastic drugs is limited by the occurrence of cardiotoxicity. Multiple genetic variants predictive…”
Get full text

Rapid COJEC Induction Therapy for High-risk Neuroblastoma Patients - Cochrane Review by Peinemann, F, van Dalen, E C, Berthold, F

“…Neuroblastoma is a rare malignant disease and patients with high-risk neuroblastoma have a poor prognosis. Rapid COJEC induction chemotherapy means (almost)…”
Get more information

Retinoic Acid for High-risk Neuroblastoma Patients after Autologous Stem Cell Transplantation - Cochrane Review by Peinemann, F, van Dalen, E C, Berthold, F

“…Neuroblastoma is a rare malignant disease and patients with high-risk neuroblastoma have a poor prognosis. Retinoic acid has been shown to inhibit growth of…”
Get more information

Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy by van Dalen, E C, van der Pal, H J H, Caron, H N, Kremer, L C M

“…The use of anthracycline chemotherapy is limited by the occurrence of cardiotoxicity. In an effort to prevent this cardiotoxicity, different anthracycline…”
Get more information

The EKZ/AMC childhood cancer survivor cohort: methodology, clinical characteristics, and data availability by Sieswerda, E., Mulder, R. L., van Dijk, I. W. E. M., van Dalen, E. C., Knijnenburg, S. L., van der Pal, H. J. H., Mud, M. S., Heinen, R. C., Caron, H. N., Kremer, L. C. M.

“…Purpose Childhood cancer survivors are at high risk of late adverse effects of cancer treatment, but there are still many gaps in evidence about these late…”
Get full text

Choice of Protein, Not Its Amyloid-Fold, Determines the Success of Amyloid-Based Scaffolds for Cartilage Tissue Regeneration by van Dalen, Maurice C.E., Karperien, Marcel, Claessens, Mireille M.A.E., Post, Janine N.

“…The formation of fibrocartilage during articular cartilage regeneration remains a clinical problem affecting adequate restoration of articular cartilage in…”
Get full text

Cardioprotective interventions for cancer patients receiving anthracyclines by van Dalen, E C, Caron, H N, Dickinson, H O, Kremer, L C M

“…Anthracyclines are among the most effective chemotherapeutic agents in the treatment of numerous malignancies. Unfortunately, their use is limited by a…”
Get more information

Pediatric oncologists and evidence-based medicine: A postal survey in The Netherlands by ten Bruggencate, M.J.M., Kremer, L.C.M., Caron, H.N., Knops, A.M., van Dalen, E.C.

“…Background The interest in evidence‐based medicine (EBM) is still increasing throughout medicine, but the precise role of EBM in the field of pediatric…”
Get full text

Treatment for asymptomatic anthracycline-induced cardiac dysfunction in childhood cancer survivors: the need for evidence by van Dalen, E C, van der Pal, H J H, van den Bos, C, Caron, H N, Kremer, L C M

Get full text

Cardiovascular Disease in Survivors of Childhood Cancer: Insights Into Epidemiology, Pathophysiology, and Prevention by Armenian, Saro H, Armstrong, Gregory T, Aune, Gregory, Chow, Eric J, Ehrhardt, Matthew J, Ky, Bonnie, Moslehi, Javid, Mulrooney, Daniel A, Nathan, Paul C, Ryan, Thomas D, van der Pal, Helena J, van Dalen, Elvira C, Kremer, Leontien C M

“…Cardiovascular disease (CVD), which includes cardiomyopathy/heart failure, coronary artery disease, stroke, pericardial disease, arrhythmias, and valvular and…”
Get full text